U.S. markets closed
  • S&P Futures

    3,650.25
    -10.75 (-0.29%)
     
  • Dow Futures

    29,125.00
    -78.00 (-0.27%)
     
  • Nasdaq Futures

    11,295.00
    -38.75 (-0.34%)
     
  • Russell 2000 Futures

    1,664.00
    -4.40 (-0.26%)
     
  • Crude Oil

    77.89
    -0.61 (-0.78%)
     
  • Gold

    1,632.60
    -3.60 (-0.22%)
     
  • Silver

    18.26
    -0.08 (-0.42%)
     
  • EUR/USD

    0.9568
    -0.0029 (-0.31%)
     
  • 10-Yr Bond

    3.9640
    +0.0860 (+2.22%)
     
  • Vix

    32.60
    +0.34 (+1.05%)
     
  • GBP/USD

    1.0679
    -0.0052 (-0.48%)
     
  • USD/JPY

    144.6750
    -0.1160 (-0.08%)
     
  • BTC-USD

    19,001.79
    -774.52 (-3.92%)
     
  • CMC Crypto 200

    435.78
    -23.36 (-5.09%)
     
  • FTSE 100

    6,984.59
    -36.36 (-0.52%)
     
  • Nikkei 225

    26,307.95
    -263.92 (-0.99%)
     

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

·1 min read
Champions Oncology, Inc.

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 618777. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46511, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/714836/Champions-Oncology-to-Announce-First-Quarter-Financial-Results-on-Thursday-September-8-2022